Ocular Therapeutix targets Q4 2026 wet AMD NDA submission
The company plans to submit its AXPAXLI NDA for wet AMD in Q4 2026 and reported a balance of $598.6M to support commercialization efforts.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day